Forgot your password?

Forgot your username?

database > company
Biovista, Inc.
HCID Member | Biotech Specialty Pharma
2421 Ivy Road
Charlottesville, VA 22903 United States
phone:(434) 989-5800
fax:(434) 971-1144
Symbol Private
Founded 2003
Employees 15
biovista.com
Research Sector Biotech Specialty Pharma
Summary Description
Repurposing drugs for unmet clinical needs
Management
Andreas Persidis Ph.D., CEO, Co-Founder; Aris Persidis Ph.D, President, Co-Founder; Graham Anthony, MBA, CFO
Keywords
intelligence products, research, clinical development, repositioning, repurpose, new use, MS, Oncology, CNS, safety, de-risk, rescue,

Comment | Printable Version | Modify profile |
Updated: May 21, 2012

Description
Biovista Inc. is dedicated to maximizing the value of research and clinical development by systematically repurposing drugs for unmet and commercially valuable medical needs. Biovista's proprietary discovery platform, termed Clinical Outcome Search Space, utilizes a predictive technology that delineates both drug efficacy and adverse effects while enabling the Company to de-risk these drugs through patient cohort stratification as well as other methods, thereby reducing the risk of failure as the drugs enter and proceed through the clinic. This unique ability to simultaneously profile efficacy and adverse effects enables Biovista & its collaborators to win on both sides of the “Benefit/Risk” equation of drug development. The Company currently has drug programs for neurological disorders, including multiple sclerosis and epilepsy, as well as for cancer, including glioblastoma and melanoma. This later-stage advisory company is collaborating with the FDA to predict safety outcomes of certain drugs, as well as with Pfizer and Novartis to find new uses for a number of their development-stage and marketed drugs.
Products / Services
Pro-active Lifecycle Extension: Biovista helps companies find new uses for their existing drugs--both for marketed drugs & pre-clinical drugs as well as finding new uses for safe drugs that didn't meet their original efficacy endpoints.

De-Risking: Biovista helps firms know what can go wrong before entering the clinic so they can stratify patient cohorts and develop their trial to avoid surprises and have a successful outcome.

Biovista has repositioned and filed for the IP on two orally available, small molecule MS therapies (BVA-101 and BVA-201) and an orally available small molecule epilepsy therapy (BVA-601) as well as two compounds targeting melanoma (BVA-501) and glioblastoma multiforme (BVA-701). Biovista has identified compounds it believes will have strong efficacy in 7 other indications as well.
Technology / Differentiation
Biovista's proprietary discovery platform, the Clinical Outcome Search Space, matches a deep multi-dimensional description of the mechanism of action (MoA) of 90,000 drugs & compounds against the MoAs of all 23,000 diseases and 6,000 adverse events known to medicine. Biovista uses this platform to evaluate the role of currently available drugs for new purposes and predict problems before they arise.

Validation: Biovista's platform has predicted strong efficacy in 3 out of 5 in vivo trials, yielding positive pre-clinical results for a first-in-class multiple sclerosis and an epilepsy therapies. It has shown strong efficacy in vitro in two Oncology compounds targeting glioblastoma multiforme & melanoma. Biovista's collaboration with the FDA has led to interesting discoveries. The FDA has licensed part of Biovista COSS technology to predict which adverse events a compound entering the FDA clinic is likely to experience.
Market / Customers
The FDA currently licenses Biovista's technology to predict potential severe adverse events for drugs entering the Clinic.

Biovista is currently negotiating agreements with 3 of the top 10 Pharma firms to reposition their existing drugs.

In October, 2010, Biovista announced a collaboration with Pfizer to find new indications for several of the compounds in Pfizer's pipeline.

Biovista is also negotiating with a large Biotech firm to find new therapies for a specific disease.

Status
As Biovista's candidates have been proven safe in prior use, Biovista believes its two MS and one epilepsy candidates can enter the clinic at the Phase IIa level for proving efficacy in man.
To date, Biovista is well funded. We do welcome inquiries from value-add investors that bring more than just money to the table.